Diabetes mellitus is the leading cause of end-stage renal disease in patients beginning renal replacement therapy. The epidemic of type 2 diabetes contributed to a new approach for diabetic kidney disease, one of the most common complications of diabetes type 1 and 2. The current recommendations of the management in diabetic kidney disease developed by an international group of experts based on analysis of clinical trials and expert opinion have been reviewed in this article. The guidelines concern several issues as renal replacement modality selection, glycaemic control, the choice of glycaemia controlling drugs and cardiovascular risk management aiming to improve the quality of life of the patients, as well as to reduce the costs of the medical care.
Keywords: cardiovascular risk; chronic kidney disease; diabetic kidney disease; diabetes mellitus.